A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma

BACKGROUND: The 5-year overall survival rate in metastatic prostate adenocarcinoma (PRAD) is extremely low. Genomic studies of PRAD have improved our understanding of disease biology. However, the role of immune checkpoint genes (ICGs) in PRAD remains unclear. METHODS: Univariate and multivariate an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Chen, Qin, Shengfei, Qiu, Shuang, Zhao, Lin, Miao, Jiaying, Chen, Yuangui, Zhou, Tie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827409/
https://www.ncbi.nlm.nih.gov/pubmed/36632155
http://dx.doi.org/10.21037/tau-22-711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827409/
https://www.ncbi.nlm.nih.gov/pubmed/36632155
http://dx.doi.org/10.21037/tau-22-711

Ejemplares similares